Rhythm Pharmaceuticals Presents First-ever Data Showing : co

-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS ---- Also presenting new hunger data from SRC1...

Related Keywords

Boston , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , Argente , Comunidad Autonoma De Aragon , Spain , Madrid , Great Britain , Ida Moeller , Elizabeth Forsythe , Megan Vogel , Sadaf Farooqi , Linda Shapiro , University College London , Cambridge Biomedical Research Centre , Faculty Of Population Health Sciences , Nasdaq , University Of Cambridge , European Union , Health Care Provider Utilization , Institute Of Metabolic Science , Rare Obesity Genetic Testing Program , European Commission , Drug Administration , Rhythm Pharmaceuticals , Clinical Research Center , European Society For Paediatric Endocrinology , Rhythm Pharmaceuticals Inc , Obesity Society Obesityweek , Department Of Pediatrics , Institute Of Child Health , Medicines Healthcare Products Regulatory Agency , Marshfield Clinic Research Institute , Obesity Society , Uncovering Rare , Chief Medical Officer , Great Ormond Street Institute , Child Health , Population Health Sciences , Bardet Biedl Syndrome , Setmelanotide Phase , Pediatric Quality , Life Inventory , Life Questionnaire Lite , Open Label Setmelanotide , Therapy Achieved Hunger Reductions , Pediatric Endocrinology , Universidad Aut , Metabolic Science , Biomedical Research Centre , Annual European Society , Paediatric Endocrinology , Biomedical Informatics , Associate Director , Medical Affairs , Pre Clinical Biology , Variants Associated , Severe Obesity , About Rhythm , Healthcare Products Regulatory Agency , New Drug Application , European Medicines Agency , Rhythm Engine , Nasdaq Rytm , Nc ,